Compare BC & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BC | TFX |
|---|---|---|
| Founded | 1845 | 1943 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 4.6B |
| IPO Year | N/A | 1994 |
| Metric | BC | TFX |
|---|---|---|
| Price | $89.07 | $115.86 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 12 | 10 |
| Target Price | $77.00 | ★ $137.11 |
| AVG Volume (30 Days) | 882.3K | ★ 940.8K |
| Earning Date | 01-01-0001 | 04-08-2026 |
| Dividend Yield | ★ 2.03% | 1.18% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,047,324,000.00 |
| Revenue This Year | $9.36 | $9.54 |
| Revenue Next Year | $5.44 | $10.52 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2.45 |
| 52 Week Low | $41.00 | $100.18 |
| 52 Week High | $90.25 | $180.58 |
| Indicator | BC | TFX |
|---|---|---|
| Relative Strength Index (RSI) | 55.85 | 57.76 |
| Support Level | $85.51 | $102.62 |
| Resistance Level | $90.25 | $115.00 |
| Average True Range (ATR) | 2.80 | 3.53 |
| MACD | -0.21 | 1.34 |
| Stochastic Oscillator | 69.34 | 79.03 |
Brunswick is a leading manufacturer in the marine recreation industry. The firm has more than 60 brands delivering products across propulsion (outboard, sterndrive, and inboard engines, propulsion-related controls, rigging, and propellers), parts, accessories, and technology, and boats (including well-known brands like Boston Whaler and Sea Ray). It also owns 442 Freedom Boat Club locations as well as Boateka, which facilitates transactions in the used-boat market. Brunswick's focus surrounds building the innovative marine and recreational experiences, technologies, and connections supported by quality and innovation.
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.